Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
McDonald's
MCD
|
$816M |
| 2 |
Crown Castle
CCI
|
$691M |
| 3 |
ATVI
Activision Blizzard Inc.
ATVI
|
$581M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$467M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$304M |
Top Sells
| 1 |
Nike
NKE
|
$1.34B |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$1.09B |
| 3 |
Amazon
AMZN
|
$671M |
| 4 |
TWX
Time Warner Inc
TWX
|
$463M |
| 5 |
NXP Semiconductors
NXPI
|
$452M |
Sector Composition
| 1 | Technology | 20.95% |
| 2 | Consumer Discretionary | 17.67% |
| 3 | Healthcare | 13.89% |
| 4 | Communication Services | 13.06% |
| 5 | Financials | 10.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
626
Invesco
IVZ
$9.81B
| $215K | ﹤0.01% |
6,100
-25,565
| -81% | -$901K |
|
627
Agilent Technologies
A
$36.5B
| $212K | ﹤0.01% |
+3,569
| New | +$212K |
|
628
Progressive
PGR
$143B
| $206K | ﹤0.01% |
4,665
-24,492
| -84% | -$1.08M |
|
629
iShares Biotechnology ETF
IBB
$5.8B
| $202K | ﹤0.01% |
+1,950
| New | +$202K |
|
630
Accenture
ACN
$159B
| $201K | ﹤0.01% |
+1,622
| New | +$201K |
|
631
Arbutus Biopharma
ABUS
$805M
| – | – |
-140,019
| Closed | -$455K |
|
632
Amgen
AMGN
$153B
| – | – |
-1,702
| Closed | -$279K |
|
633
Atara Biotherapeutics
ATRA
$90.7M
| – | – |
-1,614
| Closed | -$829K |
|
634
CommScope
COMM
$3.55B
| – | – |
-889,636
| Closed | -$37.1M |
|
635
Dover
DOV
$24.4B
| – | – |
-441,293
| Closed | -$28.6M |
|
636
Darden Restaurants
DRI
$24.5B
| – | – |
-9,927
| Closed | -$831K |
|
637
Ecolab
ECL
$77.6B
| – | – |
-2,675
| Closed | -$335K |
|
638
IMAX
IMAX
$1.6B
| – | – |
-7,978
| Closed | -$271K |
|
639
Independent Bank
INDB
$3.55B
| – | – |
-4,060
| Closed | -$264K |
|
640
Interpublic Group of Companies
IPG
$9.94B
| – | – |
-32,418
| Closed | -$797K |
|
641
iShares Russell 2000 ETF
IWM
$67.8B
| – | – |
0
| – | – |
|
642
iShares US Healthcare ETF
IYH
$2.77B
| – | – |
0
| – | – |
|
643
Lazard
LAZ
$5.32B
| – | – |
-8,385
| Closed | -$386K |
|
644
Lincoln National
LNC
$7.98B
| – | – |
-11,519
| Closed | -$754K |
|
645
Louisiana-Pacific
LPX
$6.9B
| – | – |
-1,028,148
| Closed | -$25.5M |
|
646
Marsh & McLennan
MMC
$100B
| – | – |
-9,010
| Closed | -$666K |
|
647
Norfolk Southern
NSC
$62.3B
| – | – |
-38,476
| Closed | -$4.31M |
|
|
648
NXP Semiconductors
NXPI
$57.2B
| – | – |
-4,371,606
| Closed | -$452M |
|
649
Plains GP Holdings
PAGP
$3.64B
| – | – |
-784,686
| Closed | -$24.5M |
|
650
PepsiCo
PEP
$200B
| – | – |
-5,645
| Closed | -$631K |
|